Equities

Probi AB

Probi AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)31.60
  • Today's Change0.00 / 0.00%
  • Shares traded51.73k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 16:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Probi AB's net income deteriorated -58.60% from 40.62m to 16.82m despite relatively flat revenues. A contributing factor has been the increase in the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percent of sales).
Gross margin33.18%
Net profit margin1.73%
Operating margin0.49%
Return on assets0.70%
Return on equity0.77%
Return on investment0.74%
More ▼

Cash flow in SEKView more

In 2023, Probi AB did not generate a significant amount of cash. However, the company earned 85.55m from its operations for a Cash Flow Margin of 13.63%. In addition the company used 54.17m on investing activities and also paid 23.96m in financing cash flows.
Cash flow per share9.84
Price/Cash flow per share35.68
Book value per share120.07
Tangible book value per share62.07
More ▼

Balance sheet in SEKView more

Probi AB appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio6.27
Quick ratio4.83
Total debt/total equity0.0594
Total debt/total capital0.0561
More ▼

Growth rates in SEK

SmartText is unavailable
Div yield(5 year avg)0.41%
Div growth rate (5 year)--
Payout ratio (TTM)136.09%
EPS growth(5 years)-26.09
EPS (TTM) vs
TTM 1 year ago
-20.41
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.